Last reviewed · How we verify

NCT05598632

Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry

Recruiting now Last updated 6 November 2024
What this trial tests

trial in Atrial Fibrillation in 22,000 participants. Currently enrolling.

Timeline
18 April 2023
Primary endpoint
31 December 2024
31 December 2025

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment22,000
Start date18 April 2023
Primary completion31 December 2024
Estimated completion31 December 2025
Sites1 location across China

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Adults 18 to 120, any sex, with Atrial Fibrillation or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is aimed to validate the existing stroke risk stratification model for patients with atrial fibrillation (AF) (CHA2DS2-VASc Score, CHADS2 Score, ATRIA score, ABC score, etc.) and establish a new stroke risk assessment model using a nationwide AF -specific registry in China.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Rationale, design and protocol for risk factors for stroke in patients with non-valvular atrial fibrillation in China: a nationwide registry (REFINE registry).
    Qi W, Yuan S, Liu H, Xu M, et al · · 2025 · cited 1× · PMID 41193204 · DOI 10.1136/bmjopen-2025-104806

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05598632.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing